Hyunju Kim1,2, Alice H Lichtenstein3, Kari E Wong4, Lawrence J Appel1,2,5, Josef Coresh1,2,5, Casey M Rebholz1,2. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205, USA. 2. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland, 21205, USA. 3. Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, 02111, USA. 4. Metabolon, Research Triangle Park, Morrisville, North Carolina, 27560, USA. 5. Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, 21205, USA.
Abstract
SCOPE: Serum metabolomic markers of the Dietary Approaches to Stop Hypertension (DASH) diet are previously reported. In an independent study, the similarity of urine metabolomic markers are investigated. METHODS AND RESULTS: In the DASH-Sodium trial, participants are randomly assigned to the DASH diet or control diet, and received three sodium interventions (high, intermediate, low) within each randomized diet group in random order for 30 days each. Urine samples are collected at the end of each intervention period and analyzed for 938 metabolites. Two comparisons are conducted: 1) DASH-high sodium (n = 199) versus control-high sodium (n = 193), and 2) DASH-low sodium (n = 196) versus control-high sodium. Significant metabolites identified using multivariable linear regression are compared and the top 10 influential metabolites identified using partial least-squares discriminant analysis to the results from the DASH trial. Nine out of 10 predictive metabolites of the DASH-high sodium and DASH-low sodium diets are identical. Most candidate biomarkers from the DASH trial replicated. N-methylproline, chiro-inositol, stachydrine, and theobromine replicated as influential metabolites of DASH diets. CONCLUSIONS: Candidate biomarkers of the DASH diet identified in serum replicated in urine. Replicated influential metabolites are likely to be objective biomarkers of the DASH diet.
SCOPE: Serum metabolomic markers of the Dietary Approaches to Stop Hypertension (DASH) diet are previously reported. In an independent study, the similarity of urine metabolomic markers are investigated. METHODS AND RESULTS: In the DASH-Sodium trial, participants are randomly assigned to the DASH diet or control diet, and received three sodium interventions (high, intermediate, low) within each randomized diet group in random order for 30 days each. Urine samples are collected at the end of each intervention period and analyzed for 938 metabolites. Two comparisons are conducted: 1) DASH-high sodium (n = 199) versus control-high sodium (n = 193), and 2) DASH-low sodium (n = 196) versus control-high sodium. Significant metabolites identified using multivariable linear regression are compared and the top 10 influential metabolites identified using partial least-squares discriminant analysis to the results from the DASH trial. Nine out of 10 predictive metabolites of the DASH-high sodium and DASH-low sodium diets are identical. Most candidate biomarkers from the DASH trial replicated. N-methylproline, chiro-inositol, stachydrine, and theobromine replicated as influential metabolites of DASH diets. CONCLUSIONS: Candidate biomarkers of the DASH diet identified in serum replicated in urine. Replicated influential metabolites are likely to be objective biomarkers of the DASH diet.
Authors: Mary C Playdon; Regina G Ziegler; Joshua N Sampson; Rachael Stolzenberg-Solomon; Henry J Thompson; Melinda L Irwin; Susan T Mayne; Robert N Hoover; Steven C Moore Journal: Am J Clin Nutr Date: 2017-06-28 Impact factor: 7.045
Authors: F M Sacks; E Obarzanek; M M Windhauser; L P Svetkey; W M Vollmer; M McCullough; N Karanja; P H Lin; P Steele; M A Proschan Journal: Ann Epidemiol Date: 1995-03 Impact factor: 3.797
Authors: Casey M Rebholz; Deidra C Crews; Morgan E Grams; Lyn M Steffen; Andrew S Levey; Edgar R Miller; Lawrence J Appel; Josef Coresh Journal: Am J Kidney Dis Date: 2016-08-09 Impact factor: 8.860
Authors: Ioanna Tzoulaki; Timothy M D Ebbels; Ana Valdes; Paul Elliott; John P A Ioannidis Journal: Am J Epidemiol Date: 2014-06-24 Impact factor: 4.897
Authors: Isabel Garcia-Perez; Joram M Posma; Rachel Gibson; Edward S Chambers; Tue H Hansen; Henrik Vestergaard; Torben Hansen; Manfred Beckmann; Oluf Pedersen; Paul Elliott; Jeremiah Stamler; Jeremy K Nicholson; John Draper; John C Mathers; Elaine Holmes; Gary Frost Journal: Lancet Diabetes Endocrinol Date: 2017-01-13 Impact factor: 32.069
Authors: Casey M Rebholz; Yan Gao; Sameera Talegawkar; Katherine L Tucker; Lisandro D Colantonio; Paul Muntner; Debby Ngo; Zsu Zsu Chen; Daniel Cruz; Daniel H Katz; Usman A Tahir; Clary Clish; Robert E Gerszten; James G Wilson Journal: Mol Nutr Food Res Date: 2021-03-11 Impact factor: 5.914
Authors: Queenie Chan; Gina M Wren; Chung-Ho E Lau; Timothy M D Ebbels; Rachel Gibson; Ruey Leng Loo; Ghadeer S Aljuraiban; Joram M Posma; Alan R Dyer; Lyn M Steffen; Beatriz L Rodriguez; Lawrence J Appel; Martha L Daviglus; Paul Elliott; Jeremiah Stamler; Elaine Holmes; Linda Van Horn Journal: Am J Clin Nutr Date: 2022-07-06 Impact factor: 8.472
Authors: Hyunju Kim; Cheryl Am Anderson; Emily A Hu; Zihe Zheng; Lawrence J Appel; Jiang He; Harold I Feldman; Amanda H Anderson; Ana C Ricardo; Zeenat Bhat; Tanika N Kelly; Jing Chen; Ramachandran S Vasan; Paul L Kimmel; Morgan E Grams; Josef Coresh; Clary B Clish; Eugene P Rhee; Casey M Rebholz Journal: J Nutr Date: 2021-10-01 Impact factor: 4.687